Work

Functional Imaging of Human Epidermal Growth Factor Receptor 2–Positive Breast Cancers and a Note about NOTA

Year: 2018

Type: article

Abstract: > See the associated article on page [26][1]. Breast cancer is the most common malignancy in women, and 20%–30% of these cancers overexpress the human epidermal growth factor receptor 2 (HER2) protein, making them candidates for HER2-directed therapies. Trastuzumab (Herceptin; Roche), the first

Source: Journal of Nuclear Medicine

DOI: 10.2967/jnumed.118.220905

Authors: Joanne E. Mortimer, John E. Shively

Institutions: City Of Hope National Medical Center, City of Hope, Beckman Research Institute

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2906570466